美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

12.42

+0.82007.07%

盤後：12.490.0700+0.56%19:49 EDT

成交量：32.41萬

成交額：397.15萬

市值：3,251.68萬

市盈率：- -

高：12.53

開：11.74

低：11.74

收：11.60

52周最高：36.00

52周最低：9.23

股本：261.81萬

流通股本：261.81萬

量比：1.14

換手率：12.38%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。

諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。

諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。

諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。

諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。

諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低

环球市场播报

諾和諾德首席執行官：目前無意開展重大轉型式收購交易。

諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。

諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂

諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢

諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。

諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。

諾和諾德首席財務官：我們認為我們的定價定位合理。

諾和諾德首席財務官表示：目前Wegovy口服片劑主要由患者自費購買，受市場動態影響，未來價格大概率會出現調整。

諾和諾德首席執行官：CagriSema仍是一款藥效極強的藥物。

諾和諾德首席執行官表示：我們堅信，我們擁有極為充裕的研發管線，且研發能力十分出色。

諾和諾德首席執行官：Wegovy口服片已佔據口服肥胖症藥物市場約90%的份額.

諾和諾德首席執行官：全球有150萬人服用WEGOVY藥片。

諾和諾德在TRADEGATE平台上較哥本哈根收盤價下跌5.8%。

諾和諾德股價再度下挫，Wegovy口服藥銷售意外不及預期，美國注射劑表現同樣偏弱

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/NVOX/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":12.42,"timestamp":1789675200000,"preClose":11.6,"halted":0,"volume":324061,"hourTrading":{"tag":"盘后","latestPrice":12.49,"preClose":12.42,"latestTime":"19:49 EDT","volume":3973,"amount":49599.7548,"timestamp":1789688973122,"change":0.07,"changeRate":0.005636,"amplitude":0.008052},"delay":0,"changeRate":0.07068965517241382,"floatShares":2618100,"shares":2618100,"eps":0,"marketStatus":"已收盤","change":0.82,"latestTime":"09-17 16:00:00 EDT","open":11.74,"high":12.53,"low":11.74,"amount":3971456.995836,"amplitude":0.068103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":11.6,"sharesOutstanding":4098101,"nav":11.59,"aum":30343790.59,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":11.776,"preClose":11.6,"latestTime":"09:26 EDT","volume":7827,"amount":91568.871354,"timestamp":1789651593775,"change":0.176,"changeRate":0.015172,"amplitude":0.016672},"postHourTrading":{"tag":"盘后","latestPrice":12.49,"preClose":12.42,"latestTime":"19:49 EDT","volume":3973,"amount":49599.7548,"timestamp":1789688973122,"change":0.07,"changeRate":0.005636,"amplitude":0.008052},"volumeRatio":1.144398,"impliedVol":0.7251,"impliedVolPercentile":0.288},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2618100,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.144398,"shares":2618100,"dividePrice":0,"high":12.53,"amplitude":0.068103,"preClose":11.6,"low":11.74,"week52Low":9.23,"pbRate":"--","week52High":36,"institutionHeld":0,"latestPrice":12.42,"eps":0,"divideRate":0,"volume":324061,"delay":0,"ttmEps":0,"open":11.74,"prevYearClose":21.89,"prevWeekClose":12.39,"prevMonthClose":13.84,"prevQuarterClose":16.05,"fiveDayClose":12.98,"twentyDayClose":14.64,"sixtyDayClose":15.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657003549","title":"諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657003549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657003549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:42","pubTimestamp":1785930157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","LU1093756325.SGD","OZEM","LU1093756168.USD","BK4599","NVOH","BK4588","BK4532","BK4585","IE00BKVL7J92.USD","PPH","BK4007","NVO","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539549","title":"諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657539549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:23","pubTimestamp":1785929036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOH","BK4599","BK4588","OZEM","NVOX","BK4532","THNR","BK4007","NVO","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510014","title":"諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:06","pubTimestamp":1785924365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0154236417.USD","NVOH","OZEM","NVOX","BK4585","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","THNR","IE00BKVL7J92.USD","NVO","PPH","BK4588","LU1093756325.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657107295","title":"諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657107295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657107295?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4532","BK4588","LU0154236417.USD","BK4007","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","IE00BZ1G4Q59.USD","PPH","BK4585","THNR","OZEM","LU1093756168.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510267","title":"諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510267?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:01","pubTimestamp":1785924082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","NVOX","NVO","NVOH","PPH","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4007","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","THNR","BK4585","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657551275","title":"諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657551275","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657551275?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:02","pubTimestamp":1785920520,"startTime":"0","endTime":"0","summary":"投资者持续聚焦价格压力、业绩超预期的可持续性，以及 Wegovy 口服片剂能否成为足够强劲的增长引擎，扭转公司增长颓势。诺和诺德坦言，产品降价持续拖累销售收入。不过 CEO 迈克杜斯塔达尔表示，销量持续攀升叠加 Wegovy 口服片剂初期销售表现，证明当前经营策略行之有效。周三交易开盘前，诺和诺德丹麦本土个股年内累计下跌约 5%；尽管 Wegovy 口服片剂上市后股价有所修复，但较 2024 年年中高点仍大跌近 70%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimhawm4660383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","LU0154236417.USD","PPH","NVOH","LU1093756168.USD","LU1093756325.SGD","OZEM","THNR","BK4588","BK4532","IE00BKVL7J92.USD","BK4585","NVO","BK4007","IE00BZ1G4Q59.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511799","title":"諾和諾德首席執行官：目前無意開展重大轉型式收購交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756168.USD","THNR","PPH","BK4585","NVO","OZEM","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOH","NVOX","BK4007","BK4588","LU1093756325.SGD","BK4599","BK4532","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511459","title":"諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511459?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:26","pubTimestamp":1785918369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","NVOH","BK4532","BK4599","LU0154236417.USD","LU1093756168.USD","NVO","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD","THNR","BK4007","BK4588","PPH","IE00BKVL7J92.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519148","title":"諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519148?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:49","pubTimestamp":1785916176,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Q2业绩超预期、上调全年指引却难掩隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOH","IE00BZ1G4Q59.USD","BK4588","LU1093756168.USD","NVO","LU0154236417.USD","BK4007","NVOX","IE00BKVL7J92.USD","THNR","BK4532","BK4585","PPH","LU1093756325.SGD","OZEM","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657403515","title":"諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢","url":"https://stock-news.laohu8.com/highlight/detail?id=2657403515","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657403515?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913213,"startTime":"0","endTime":"0","summary":"“Cagrisema再次令人失望，这可能凸显了诺和诺德面临的最大战略问题。”他表示，这些令人失望的结果将促使诺和诺德加快研发步伐并更加积极地寻求合作机会，而非变得更加谨慎。“这将诺和诺德的研发管线及其稳健性推到了聚光灯下，”AL Sydbank在致客户的报告中表示，并补充道，尽管诺和诺德的业绩本应让投资者松一口气，但这些数据和减值准备却打击了市场情绪。他表示，当务之急是扩大研发管线，同时保持生产效率的纪律性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","NVOX","NVO","NVOH","PPH","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4007","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","THNR","BK4585","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657251339","title":"諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657251339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657251339?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:28","pubTimestamp":1785911326,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","THNR","IE00BKVL7J92.USD","OZEM","BK4588","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4007","BK4532","NVO","BK4585","LU1093756168.USD","NVOX","LU1093756325.SGD","NVOH","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657151338","title":"諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657151338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657151338?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:23","pubTimestamp":1785911038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","NVOH","NVOX","OZEM","BK4007","NVO","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4588","LU0154236417.USD","LU1093756168.USD","PPH","BK4532","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657187875","title":"諾和諾德首席財務官：我們認為我們的定價定位合理。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657187875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657187875?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:15","pubTimestamp":1785910546,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","NVOH","BK4532","BK4599","LU0154236417.USD","LU1093756168.USD","NVO","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD","THNR","BK4007","BK4588","PPH","IE00BKVL7J92.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518786","title":"諾和諾德首席財務官表示：目前Wegovy口服片劑主要由患者自費購買，受市場動態影響，未來價格大概率會出現調整。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518786?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:15","pubTimestamp":1785910533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","NVOX","NVO","BK4588","OZEM","THNR","PPH","BK4585","BK4007","NVOH","LU1093756325.SGD","BK4599","BK4532","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518782","title":"諾和諾德首席執行官：CagriSema仍是一款藥效極強的藥物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518782?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:14","pubTimestamp":1785910446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","PPH","NVOX","LU0154236417.USD","BK4585","THNR","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4599","NVO","OZEM","LU1093756325.SGD","LU1093756168.USD","NVOH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518282","title":"諾和諾德首席執行官表示：我們堅信，我們擁有極為充裕的研發管線，且研發能力十分出色。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518282?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:12","pubTimestamp":1785910332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","LU1093756168.USD","BK4599","BK4532","IE00BKVL7J92.USD","THNR","NVOH","BK4588","BK4007","LU1093756325.SGD","NVOX","NVO","BK4585","LU0154236417.USD","OZEM","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657115518","title":"諾和諾德首席執行官：Wegovy口服片已佔據口服肥胖症藥物市場約90%的份額.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657115518","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657115518?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:07","pubTimestamp":1785910062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756325.SGD","NVO","NVOH","OZEM","BK4585","IE00BKVL7J92.USD","LU1093756168.USD","NVOX","THNR","BK4599","BK4007","BK4532","PPH","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657751818","title":"諾和諾德首席執行官：全球有150萬人服用WEGOVY藥片。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657751818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657751818?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:04","pubTimestamp":1785909894,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4585","NVO","LU1093756168.USD","NVOX","BK4588","BK4007","OZEM","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","NVOH","BK4532","PPH","THNR","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657590904","title":"諾和諾德在TRADEGATE平台上較哥本哈根收盤價下跌5.8%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657590904","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657590904?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 13:34","pubTimestamp":1785908052,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4599","BK4532","LU0154236417.USD","THNR","OZEM","IE00BZ1G4Q59.USD","BK4585","NVOX","IE00BKVL7J92.USD","NVO","NVOH","LU1093756325.SGD","PPH","BK4588","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177186111","title":"諾和諾德股價再度下挫，Wegovy口服藥銷售意外不及預期，美國注射劑表現同樣偏弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1177186111","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177186111?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 10:42","pubTimestamp":1785897771,"startTime":"0","endTime":"0","summary":"诺和诺德提前公布第二季度业绩，Wegovy口服药销售额为322亿丹麦克朗，低于市场预期的332亿丹麦克朗，美国市场Wegovy注射剂销售也不及预期，拖累股价表现。虽然公司上调全年销售展望，二季度整体收入及肥胖药业务仍保持增长，但投资者对其GLP-1产品增长速度以及与礼来竞争的压力仍较为敏感。","market":"us","thumbnail":"https://community-static.tradeup.com/news/4c2ed3b4ebfd5dba1ba58ba649ecd2c2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/4c2ed3b4ebfd5dba1ba58ba649ecd2c2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","NVO","NVOX"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}